No growth in revenue compared to H2 2021. Soaring expenses. Continued failure to execute on new products. Existing product runway facing imminent patent expiry. Incredibly overvalued.
Ann: 2022 Half Year Financial Results, page-3
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.04 |
Change
-0.010(0.33%) |
Mkt cap ! $921.1M | |||
| Open | High | Low | Value | Volume |
| $2.99 | $3.06 | $2.94 | $2.324M | 770.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $3.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.04 | 621 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| NAN (ASX) Chart |